CNSA Clinical Proceedings is a series of educational resources intended to raise awareness about unmet needs in neurology.
Alzheimer's Disease Psychosis
CNSA’s inaugural white paper focuses on Alzheimer’s disease psychosis and is currently under development.
This paper will convey the clinical perspectives as to the challenges in treating patients with Alzheimer’s disease psychosis when no approved therapy is available. The white paper will also explore the impact of the unmet needs of Alzheimer’s disease psychosis on patients, clinicians, caregivers and the health care system, as well as societal ramifications.
The expert panel for this paper is:
- Howard S. Kirshner, MD – Chair
- Christina Mayville, MD
- Jeffrey L. Cummings, MD
- Patrick Griffith, MD
- William Petrie, MD
The expert panel will consider the following topics:
- The burden of behavioral and psychological consequences of Alzheimer’s disease.
- Factors that increase the burden of Alzheimer’s disease psychosis.
- The role of neurologists, geriatric psychiatrists, internists, and geriatricians in treating Alzheimer’s disease psychosis.
- The role of caregivers and long-term care clinicians in supporting patients experiencing the disease.
- The impact of the lack of approved therapies for Alzheimer’s disease psychosis.
- The cost to patients, their families, the health care system and society of untreated Alzheimer’s disease psychosis.
The inaugural Clinical Proceedings white paper is being supported in part with a grant from Acadia Pharmaceuticals.